Фармакология полипренолов как адаптогенов, снижающих интенсивность процессов гликирования



Цитировать

Полный текст

Аннотация

На сегодняшний день большое внимание уделяется процессу гликирования, играющему важную роль в патогенезе сосудистых осложнений сахарного диабета, различных нейродегенеративных заболевниях. В результате необратимых превращений продуктов раннего гликирования образуются стабильные соединения различной структуры - конечные продукты глубокого гликирования (КПГ), обладающие характерными особенностями, приводящими к патологическим проявлениям. К специфическим рецепторам КПГ относятся рецептор фагоцитов, рецептор конечных продуктов гликирования (RAGE - receptor for advanced glycation end products) и галектин-3. Необходимо найти способы предотвращения развития негативных процессов, вызванных гликированием. Они могут заключаться в применении ингибиторов гликирования или в применении веществ, приводящих к снижению уровня продуктов гликирования, также в усилении метаболических процессов, которые могут способствовать снижению уровня гликирования, и в подавлении взаимодействия с рецептором и/или пострецепторных сигнальных путей, которое также теоретически может снизить риск развития негативных явлений, вызванных продуктами гликирования. Полипренолы являются биологически высокофункционально активными веществами, участвующими в процессе биосинтеза полисахаридов, гликопротеидов, пептидогликанов и углеводсодержащих биополимеров, и являются перспективными соединениями, применение которых возможно в различных областях экспериментальной и клинической медицины.

Об авторах

Наталья Сергеевна Бакунина

ФГБУ «Научно-исследовательский институт экспериментальной медицины» СЗО РАМН

Email: pdshabanov@mail.ru
аспирант отдела нейрофармакологии им. С. В. Аничкова

Руслан Иванович Глушаков

ГБОУ ВПО «Государственная медицинская педиатрическая академия» Министерства здравоохранения РФ

Email: glushakovruslan@gmail.com
к. м. н., врач онколог-гинеколог

Наталья Игоревна Тапильская

ГБОУ ВПО «Государственная медицинская педиатрическая академия» Министерства здравоохранения РФ

д. м. н., профессор кафедры акушерства и гинекологии с онкологией

Петр Дмитриевич Шабанов

ФГБУ «Научно-исследовательский институт экспериментальной медицины» СЗО РАМН

Email: pdshabanov@mail.ru
д. м. н., профессор, заведующий отделом нейрофармакологии им. С. В. Аничкова

Список литературы

  1. Гусев Е. И., Скворцова В. И. Ишемия головного мозга. - М.: Медицина, 2001. - 328 с.
  2. Adami C., Bianchi R., Pula G., Donato R. S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain // Biochim. Biophys. Acta. - 2004. - Vol. 1742. - P. 169-177.
  3. Adami C., Sorci G., Blasi E. et al. S100B expression in and effects on microglia // Glia. - 2001. - Vol. 33. - P. 131-142.
  4. Ahmed N., Thornalley P. J., Dawczynski J. et al. Methylglyoxal-derived hydroimidazolone advanced glycation endproducts of human lens proteins // Invest. Ophthalmol. Vis. Sci. - 2003. - Vol. 44. - P. 5287-5292.
  5. Ahmed N., Thornalley P. J., Luthen R. et al. Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis // J. Hepatol. - 2004. - Vol. 41. - P. 913-919.
  6. Allore R., O’Hanlon D., Price R. et al. Gene encoding the β subunit of S100 protein is on chromosome 21: implications for Down’s syndrome // Science. - 1988. - Vol. 239. - P. 1311-1313.
  7. Bagrov A. Y., Dmitrieva R. I., Fedorova O. V. et al. Endogenous marinobufagenin-like immunoreactive substance - A possible endogenous Na/K-ATPase inhibitor with vasoconstrictor activity // Amer. J. Hypertens. - 1996. - Vol. 9. - P. 982-990.
  8. Bagrov Y. Y., Manusova N. B., Frolova E. V. et al. Endogenous sodium pump inhibitors, diabetes mellitus and preeclampsia Preliminary observations and a hypothesis // Pathophysiology. - 2007. - Vol. 14, N 3-4. - P. 147-151.
  9. Barger S. W., Wolchok S. R., Van Eldik L. J. Disulfide-linked S100β dimers and signal transduction // Biochim. Biophys. Acta. - 1992. - Vol. 1160. - P. 105-112.
  10. Ostendorp T., Heizmann C. W., Kroneck P. M., Fritz G. Purification, crystallization and preliminary X-ray diffraction studies on human Ca 2+-binding protein S100B // Acta Crystallograph. Sect. F Struct. Biol. Cryst. Commun. - 2005. Vol. 61, Pt. 7. - P. 673-675.
  11. Berlanga J., Cibrian D., Guillen I. et al. Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of skin wounds // Clin. Sci. - 2005. - Vol. 109. - P. 83-95.
  12. Bianchi R., Adami C., Giambanco I., Donato R. S100B binding to RAGE in microglia stimulates COX-2 expression // J. Leukoc. Biol. - 2007. - Vol. 81, № 1. - P. 108-118.
  13. Bidmon C., Frischmann M., Pischetsrieder M. Analysis of DNA-bound advanced glycation end-products by LC and mass spectrometry // J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. - 2007. - Vol. 855, N 1. - P. 51-58.
  14. Birrell A. M., Heffernan S. J., Ansselin A. D. et al. Functional and structural abnormalities in the nerves of type I diabetic baboons: aminoguanidine treatment does not improve nerve function // Diabetologia. - 2000. - Vol. 43, N 1. - P. 110-116.
  15. Cantagrel V., Lefeber D. J., Ng B. G. et al. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder // Cell. - 2010. - Vol. 142, N 2. - P. 203-217.
  16. Cartier L., Hartley O., Dubois-Dauphin M., Krause K. H. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases // Brain Res. Brain Res. Rev. - 2005. - Vol. 48. - P. 16-42.
  17. Colaco C. A., Ledesma M. D., Harrington C. R., Avila J. The role of the Maillard reaction in other pathologies: Alzheimer's disease // Nephrol. Dial. Transplant. - 1996. - Vol. 11, Suppl. 5. - P. 7-12.
  18. Craft J. M., Watterson D. M., Marks A., Van Eldik L. J. Enhanced susceptibility of S-100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human β-amyloid // Glia. - 2005. - Vol. 51. - P. 209-216.
  19. DeFronzo R. A., Bonadonna R., Ferrannini E. Pathogenesis of NIDDM: a balanced overview // Diabetes Care. - 1992. - Vol. 15. - P. 318-368.
  20. Degenhardt T. P., Thorpe S. R., Baynes J. W. Chemical modification of proteins by methylglyoxal // Cell Mol. Biol. - 1998. - Vol. 44. - P. 1139-1145.
  21. Donato R. (2001) S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles // Int. J. Biochem. Cell Biol. - 2001. - Vol. 33. - P. 637-668.
  22. Feng L., Matsumoto C., Schwartz A. et al. Chronic vascular inflammation in patients with Type 2 diabetes: endothelial biopsy and RT-PCR analysis // Diabetes Care. - 2005. - Vol. 28. - P. 379-384.
  23. Flier J. S., Edwards M. W., Daly J. W., Myers C. W. Widespread occurrence in frogs and toads of skin compounds interacting with the ouabain site of Na+/K+-ATPase // Science. - 1989. - Vol. 208. - P. 503-505.
  24. Gallet X., Charloteaux B., Thomas A., Braseur R. A fast method to predict protein interaction sites from sequences // J. Mol. Biol. - 2000. - Vol. 302. - P. 917-926.
  25. Goldberg A. L. Protein degradation and protection against misfolded or damaged proteins // Nature. - 2003. - Vol. 426. - P. 895-899.
  26. Guarini M., Stabile A., Cavallini G. et al. Effects of oxidative stress on the Dolichol content of isolated rat liver cells // Free Radic Res. - 2007. - Vol. 41, N 11. - P. 1283-1288.
  27. Gutteridge J. M., Halliwell B. Antioxidants: Molecules, medicines, and myths // Biochem. Biophys. Res. Commun. - 2010. - Vol. 393, N 4. - P. 561-564.
  28. Hooff G. P., Wood W. G., Müller W. E., Eckert G. P. Isoprenoids, small GTPases and Alzheimer's disease // Biochim. Biophys. Acta. - 2010. - Vol. 1801, N 8. - P. 896-905.
  29. Griffin W. S., Sheng J. G., Royston M. C. et al. Glial-neuronal interactions in Alzheimer’s disease: the potential role of a “cytokine cycle” in disease progression // Brain Pathol. - 1998. - Vol. 8. - P. 65-72.
  30. Gründahl J. E., Guan Z., Rust S. et al. Life with too much polyprenol: polyprenol reductase deficiency // Mol. Genet. Metab. - 2012. - Vol. 105, N 4. - P. 642-651.
  31. Hauwel M., Furon E., Canova C. et al. Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglia, astrocytes, “protective” glial stem cells and stromal ependymal cells // Brain Res. Brain Res. Rev. - 2005. - Vol. 48. - P. 220-233.
  32. Hofmann M. A., Drury S., Fu C. et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides // Cell. - 1999. - Vol. 97. - P. 889-901.
  33. Hu J., Castets F., Guevara J. L., Van Eldik L. J. S100β stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes // J. Biol. Chem. - 1996. - Vol. 271. - P. 2543-2547.
  34. Huttunen H. J., Kuja-Panula J., Sorci G. et al. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through RAGE activation // J. Biol. Chem. - 2000. - Vol. 275. - P. 40 096-40 105.
  35. Johnson R. N., Easdale R. W., Tatnell M., Baker J. R. Significance of variation in turnover of glycated albumin on indexes of diabetic control // Clin. Chim. Acta. - 1991. - Vol. 198. - P. 229-238.
  36. Keller R. K., Mitchell D. A., Goulah C. C., Fliesler S. J. Hepatic isoprenoid metabolism in a rat model of Smith-Lemli-Opitz Syndrome // Lipids. - 2013. - Vol. 48, N 3. - P. 219-229.
  37. Kligman D., Marshak D. R. Purification and characterization of a neurite extension factor from bovine brain // Proc. Natl. Acad. Sci. USA. - 1985. - Vol. 82. - P. 7136-7139.
  38. Kurup R. K., Kurup P. A. Isoprenoid pathway-related membrane dysfunction in neuropsychiatric disorders // Int. J. Neurosci. - 2003. - Vol. 113, N 11. - P. 1579-1591.
  39. Kuzuyama T., Seto H. Two distinct pathways for essential metabolic precursors for isoprenoid biosynthesis // Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. - 2012. - Vol. 88, N 3. - P. 41-52.
  40. Liu L., Li Y., Van Eldik L. J. et al. S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors // J. Neurochem. - 2005. - Vol. 92. - P. 546-553.
  41. Malaisse W. J. Glucose-sensing by the pancreatic -cell: the mitochondrial part // Int. J. Biochem. - 1992. - Vol. 24. - P.693-701.
  42. Martiney J. A., Cuff C., Litwak M. et al. Cytokine-induced inflammation in the central nervous system revisited // Neurochem. Res. - 1998. - Vol. 23. - P. 349-359.
  43. Marquardt T., Denecke J. Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies // Eur. J. Pediatr. - 2003. - Vol. 162. - P. 359-379.
  44. McCarty M. F. Can correction of sub-optimal coenzyme Q status improve-cell function in type II diabetics? // Medical Hypotheses. - 1999. - Vol. 52. - P. 397-400.
  45. McDonnell M. R., Archbold G. P. R. Plasma ubiquinol/cholesterol ratios in patients requiring dialysis // Clin Chim Acta. - 1996. - Vol. 91. - P. 10 878-10 882.
  46. Min W., Pober J. S. TNF initiates E-selectin transcription in human endothelial cells through parallel TRAF-NF-B and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 pathways // J. Immunol. - 1997. - Vol. 159. - P. 3508-3518.
  47. Medina L., Haltiwanger R. Calf thymus high mobility group proteins are nonenzymatically glycated but not significantly glycosylated // Glycobiology. - 1998. - Vol. 8. - P. 191-198.
  48. Monte Alegre S., Saad S. T., Delatre E., Saad M. J. Insulin secretion in patients deficient in glucose-6-phosphate dehydrogenase // Horm. Metab. Res. - 1999. - V. 23. - P.171-173.
  49. Mrak R. E., Griffin W. S. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease // Neurobiol. Aging. - 2001. - Vol. 22. - P. 915-922.
  50. Ng R., Argirov O. K., Ahmed N. et al. Human serum albumin minimally modified by methylglyoxal binds to human mononuclear leukocytes via the RAGE receptor and is displaced by N-carboxymethyl-lysine and hydroimidazolone AGE epitopes // Int. Congr. Ser. - 2002. - Vol. 1245. - P. 77-81.
  51. Park J. S., Svetkauskaite D., He Q. et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein // J. Biol. Chem. - 2004. - Vol. 279. - P. 7370-7377.
  52. Petrova T. V., Hu J., Van Eldik L. J. Modulation of glial activation by astrocyte-derived protein S100B: differential responses of astrocyte and microglial cultures // Brain Res. - 2000. - Vol. 853. - P. 74-80.
  53. Reali C., Scintu F., Pillai R. et al. S100B counteracts effects of the neurotoxicant trimethyltin on astrocytes and microglia // J. Neurosci. Res. - 2005. - Vol. 81. - P. 677-686.
  54. Reddy P. H., McWeeney S., Park B. S. et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease // Hum. Mol. Genet. - 2004. - Vol. 13, N 12. - P. 1225-1240.
  55. Requena J. R., Baynes J. W., Sima A. A. F. Chronic Complications in Diabetes: Animal Models and Chronic Complications. Studies in animal models on the role of glycation and advanced glycation endproducts (AGEs) in the pathogenesis of diabetic complications: pitfalls and limitations. - Amsterdam: Harwood Acad. Publ., 2000. - P. 43-70.
  56. Schmidt A. M., Yan S. D., Yan S. F., Stern D. M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses // J. Clin. Invest. - 2001. - Vol. 108. - P. 949-955.
  57. Smedsrod B., Melkko J., Araki N. et al. Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells // Biochem. J. - 1997. - Vol. 322. - P. 567-573.
  58. Stehouwer C. D. A., Gall M. A., Twisk J. W. R. et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic lowgrade inflammation in type 2 diabetes // Diabetes. -2002. - Vol. 51. - P. 1157-1165.
  59. Stocker R., Bowry V. W., Frei B. Ubiquinol-10 protects human low-density lipoprotein more efficiently against lipid peroxidation than does -tocopherol // Proc. Natl. Acad. Sci. USA. - 1991. - Vol. 88. - P. 1646-1650.
  60. Svistounov D. N., Berg T. J., Mccourt P. A. G. et al. Lack of recognition of N-epsilon- (carboxymethyl) lysine by the mouse liver reticulo-endothelial system: implications for pathophysiology // Biochem. Biophys. Res. Commun. - 2003. - Vol. 309. - P. 786-791.
  61. Takata K., Horiuchi S., Araki N. et al. Endocytic uptake of non-enzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde modified proteins // J. Biol. Chem. - 1988. - Vol. 268. - P. 14189-14825.
  62. Thornalley P. J., Battah S., Ahmed N. et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry // Biochem. J. - 2003. - Vol. 375. - P. 581-592.
  63. Thornalley P. J. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs // Cell. Mol. Biol. - 1998. - Vol. 44. - P. 1013-1023.
  64. Thornalley P. J. Clinical significance of glycation // Clin. Lab. - 1999. - Vol. 45. - P. 263-273.
  65. Treutiger C. J., Mullins G. E., Johansson A. S. M. et al. High mobility group 1 B-box mediates activation of human endothelium // J. Intern. Med. - 2003. - Vol. 254. - P. 375-385.
  66. Town T., Nikolic V., Tan J. The microglial “activation” continuum: from innate to adaptive responses // J. Neuroinflammation. - 2005. - Vol. 2. - P. 24.
  67. Valencia J. V., Mone M., Zhang J. et al. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA // Diabetes. - 2004. - Vol. 53. - P. 743-751.
  68. Van Eldik L. J., Wainwright M. S. (2003) The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain // Restor. Neurol. Neurosci. - 2003. - Vol. 21. - P. 97-108.
  69. Vlassara H., Fuh H., Donnelly T., Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits // Mol. Med. - 1995. - Vol. 1. - P. 447-456.
  70. Vlassara H., Fuh H., Makita Z. et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications // Proc. Natl. Acad. Sci. USA. - 1992. - Vol. 89. - P. 12043-12047.
  71. Vlassara H., Li Y. M., Imani F. et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor family // Mol. Med. - 1995. - Vol. 1. - P. 634-646.
  72. Vlassara H., Striker L. J., Teichberg S. et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats // Proc. Natl. Acad. Sci. USA. - 1994. - Vol. 91. - P. 11704-11708.
  73. Wainwright M. S., Craft J. M., Griffin W. S. et al. Increased susceptibility of S100B transgenic mice to perinatal hypoxia-ischemia // Ann. Neurol. - 2004. - Vol. 56. - P. 61-67.
  74. Watts G. F., Playford D. A., Croft K. D. et al. Coenzyme Q10 improves endothelial dysfunction of the brachial artery in type II diabetes mellitus // Diabetologia. - 2002. - Vol. 45. - P. 420-426.
  75. Watts G. F., Playford D. Dislipoproteinemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in NIDDM: an hypothesis // Atherosclerosis. - 1998. - Vol. 141. - P. 17-31.
  76. Westwood M. E., Thornalley P. J. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins // J. Protein Chem. - 1995. - Vol. 14. - P. 359-372.
  77. Winningham-Major F., Staecker J. L., Barger S. W. et al. Neurite extension and neuronal survival activities of recombinant S100β proteins that differ in the content and position of cysteine residues // J. Cell Biol. - 1989. - Vol. 109, N 6, Pt. 1. - P. 3063-3071.
  78. Yonekura H., Yamamoto Y., Sakurai S. et al. Novel splice variants of the receptor for advanced glycation endproducts expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury // Biochem. J. - 2003. - Vol. 370. - P. 1097-1109.
  79. Winningham-Major F., Staecker J. L., Barger S. W. et al. (1989) Neurite extension and neuronal survival activities of recombinant S100β proteins that differ in the content and position of cysteine residues // J. Cell Biol. - 1989. - Vol. 109, N 6, Pt. 1. - P. 3063-3071.
  80. Yonekura H., Yamamoto Y., Sakurai S. et al. Novel splice variants of the receptor for advanced glycation endproducts expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury // Biochem. J. - 2003. - Vol. 370. - P. 1097-1109.

© Бакунина Н.С., Глушаков Р.И., Тапильская Н.И., Шабанов П.Д., 2013

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах